Maxvoid Plus 8 CP Tablet
By Maxvoid Plus
Rx
30 Tablet in a Strip

Composition
Silodosin(8mg) + Dutasteride(0.5mg)

Manufacturer - Alkem Laboratories Ltd
Alkem Laboratories Limited, Devashish Building, Alkem House, Senapati Bapat Road, Lower Parel, Mumbai - 400 013.

Expires on or after
October, 2025
About Maxvoid Plus 8 CP Tablet
Maxvoid Plus 8 CP Tablet is a medication designed to help men who suffer from an enlarged prostate gland, a condition known as benign prostatic hyperplasia (BPH). This tablet combines two medicines, Silodosin and Dutasteride, to effectively manage the symptoms associated with an enlarged prostate. BPH can lead to difficulty urinating, frequent urges to urinate, and other bothersome urinary symptoms. Silodosin, an alpha-1 blocker, works by relaxing the smooth muscles in the bladder and prostate, thereby improving urination flow. On the other hand, Dutasteride, a 5-alpha reductase inhibitor, reduces the production of dihydrotestosterone, a hormone that contributes to prostate enlargement, resulting in the shrinkage of the enlarged prostate and alleviation of BPH symptoms in men.
Patients taking Maxvoid Plus 8 CP Tablet are advised to follow their doctor's prescribed dosage regimen carefully and take the tablet at the same time each day. It is crucial to consume the tablet whole and not break, chew, or crush it. Although it may take up to 4 weeks to observe improvements in symptoms, it is essential to continue taking the medication regularly as directed by the healthcare provider. In case the symptoms do not improve or worsen after this period, it is important to inform the doctor promptly.
Like any medication, Maxvoid Plus 8 CP Tablet may cause side effects. Common side effects include decreased libido, erectile dysfunction, breast tenderness, breast enlargement, dizziness, and drowsiness. If any of these side effects persist or become concerning, seeking advice from a healthcare professional is recommended. Patients should also be aware that the risks of these side effects may be higher at the beginning of treatment but are outweighed by the benefits of the medication in managing BPH symptoms.
It is important to note that Maxvoid Plus 8 CP Tablet is specifically designed for adult men with an enlarged prostate and should not be taken by women or children. Patients are advised to inform their doctor of any existing medical conditions, such as low blood pressure or liver and kidney diseases, before starting this medication. Additionally, informing the doctor about all other medications being taken is crucial to avoid any potential drug interactions. Patients should abstain from alcohol consumption while on Maxvoid Plus 8 CP Tablet, as it may exacerbate side effects like dizziness and low blood pressure.
In summary, Maxvoid Plus 8 CP Tablet offers an effective treatment option for men with BPH, helping to alleviate urinary symptoms and improve overall quality of life. Following the prescribed dosage regimen, being aware of potential side effects, and seeking medical advice when needed are essential steps in managing this condition with this medication.
Disclaimer
The information provided on this website is to the best of our abilities to ensure it is accurate, reliable, and reviewed by a team of professionals. It should not be used to diagnose, prevent, or cure any health problem. The information presented here is not intended to create a doctor-patient relationship or replace a registered medical practitioner's advice, diagnosis, or treatment. The absence or provision of any information or warning regarding any medicine should not be assumed as an implied or explicit assurance of safety or efficacy. We highly recommend consulting your registered medical practitioner for all queries or doubts related to your medical condition. Do not ignore professional medical advice or delay seeking it based on the content encountered on our website. We intend to support, not replace, the doctor-patient relationship.
₹1300
Inclusive of all taxes
Content verified by

Dr. Archana Prabhakar
MBBS, M.Med (Family Medicine)
Last update on 07-Oct-2024